8-K/A: Profusa Amends Merger Filing, Reveals Lock-Ups & Financials

Profusa, Inc. filed an amended 8-K, detailing post-merger lock-up agreements, unaudited Q2 2025 financials, and management's discussion, highlighting ongoing liquidity concerns despite recent capital infusion.

Summary

• Profusa, Inc. filed an amendment to its July 18, 2025 Current Report on Form 8-K, primarily to include details of the Sponsor Lock-Up Agreement, unaudited condensed consolidated financial statements for Legacy Profusa as of and for the three and six months ended June 30, 2025 and 2024, and the related Management's Discussion and Analysis.
• The filing also corrected an inadvertently filed version of the Stockholder Lock-Up Agreement.
• The Business Combination with NorthView Acquisition Corp. was completed on July 11, 2025, with Profusa becoming a wholly-owned subsidiary of the renamed New Profusa, Inc.
• Legacy Profusa reported a net loss of $2.3 million for the three months ended June 30, 2025, and $5.1 million for the six months ended June 30, 2025, compared to $2.0 million and $4.5 million for the respective periods in 2024.
• Cash used in operating activities increased to $1.1 million for the six months ended June 30, 2025, from $1.0 million in the prior year period.
• As of June 30, 2025, the company had a working capital deficit of approximately $63.2 million and total liabilities of $63.4 million.
• Management believes that the liquidity obtained from the Business Combination, including $1.3 million from the NorthView trust account and a $9.0 million net PIPE convertible note, is not sufficient to alleviate substantial doubt about the company's ability to continue as a going concern within one year from the financial statements' issuance date (August 2026).
• Post-merger, various convertible notes and preferred stock were converted into New Profusa common stock, and an Equity Line of Credit (ELOC) agreement for up to $100 million was entered into with Ascent on July 28, 2025.

Sentiment

Score: 3

Explanation: While the completion of the merger and securing an ELOC provide some capital, the company's financial position remains precarious with increasing net losses, a substantial working capital deficit, and explicit management statements about ongoing going concern doubts. The delays in milestones and defaults on existing loans further contribute to a negative sentiment, despite the long-term potential of its products.

Positives

• Successful completion of the Business Combination with NorthView Acquisition Corp. on July 11, 2025.
• Receipt of $1.3 million cash from the NorthView trust account and a $9.0 million net PIPE convertible note as part of the merger closing, providing immediate liquidity.
• Entry into an Equity Line of Credit (ELOC) agreement with Ascent on July 28, 2025, allowing the company to potentially raise up to $100 million in additional capital.
• The Lumee Oxygen platform has received CE mark approval in Europe, indicating market readiness in that region.
• Ongoing clinical trials for the Lumee Glucose platform, a continuous glucose monitoring system designed for non-surgical insertion.

Negatives

• Incurred significant net losses: $2.3 million for Q2 2025 and $5.1 million for the six months ended June 30, 2025, representing an increase from prior year periods.
• Increased cash used in operating activities: $1.1 million for the six months ended June 30, 2025.
• Substantial working capital deficit of approximately $63.2 million as of June 30, 2025.
• Management explicitly states that the recent capital infusion is not sufficient to alleviate substantial doubt about the company's ability to continue as a going concern within one year.
• The company is in default on its PPP Loan 2 due to non-payment and is incurring late penalties.
• The Tasly Convertible Debt, a related party loan, is in default and incurring a 24% default interest rate.
• Government grant revenue decreased to $0 for the three and six months ended June 30, 2025, from $25,000 in the prior year periods.
• Increased loss on change in the fair value of related party Tasly convertible debt, from $(15) thousand to $(57) thousand for the three months ended June 30, 2025, and from $(11) thousand to $(118) thousand for the six months ended June 30, 2025.

Risks

• Ability to obtain future financing to maintain current operations and support product commercialization efforts.
• Advances and trends in new technologies and industry standards could impact product competitiveness.
• Uncertainty regarding the results of clinical trials for product candidates.
• Risk of not receiving necessary regulatory approvals (e.g., FDA clearance for Lumee Oxygen in the U.S.) or delays in approval.
• Challenges in developing effective sales channels and strategic relationships.
• Potential litigation or claims based on intellectual property, patent, product, or regulatory factors.
• Ability to attract and retain employees necessary to support growth.
• Impact of stubbornly high inflation, monetary policy normalization, and tightening global financial conditions.
• Risk of a disorderly tightening of financial conditions amplified by built-up vulnerabilities.
• Adverse effects from instability or changes in a country's or region's economic conditions, laws, or regulations.
• Increased difficulty of conducting business due to actual or potential political or military conflict.
• Actions by governments that may restrict the ability to transact business in foreign countries or with certain foreign entities.
• Possible slowdown in global trade caused by increasing tariffs or other restrictions.
• Climate-related events, including extreme weather and natural disasters, affecting critical infrastructure, operations, users, or third-party suppliers.

Future Outlook

The company expects to continue making substantial investments in building its European and United States commercial infrastructure, enhancing existing products, and developing new ones. It also aims to continue discussions with potential partners in Asia for the APAC Joint Venture. Additional expenses are anticipated due to operating as a public company, including compliance, insurance, and investor relations. The company expects to require additional financing through equity offerings, debt financings, or credit facilities to fund operations and planned growth, especially for periods beyond twelve months from the financial statements' issuance. Proceeds from the ELOC agreement may be used to purchase Bitcoin if the cash balance exceeds $5 million, otherwise to first bring the balance to $5 million.

Management Comments

• Management expects to continue to incur additional substantial losses in the foreseeable future as a result of research and development activities.
• Management believes this liquidity [from the merger and PIPE] is not sufficient to alleviate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued in August 2026.
• It is our expectation to continue to make substantial investments in building its European and United States commercial infrastructure and enhancing existing products and developing new ones.
• We aim to continue discussions with potential partners in Asia.
• We expect to incur additional expenses due to operating as a public company, including expenses related to compliance with the rules and regulations of the U.S. Securities and Exchange Commission, or the SEC, and those of the Nasdaq Stock Market LLC (NASDAQ) Stock Market, additional insurance expenses, investor relations activities and other administrative, professional and consulting services.

Industry Context

Profusa operates in the rapidly evolving digital health and medical technology sectors, specifically focusing on biosensing solutions like continuous glucose monitoring (CGM) and tissue oxygen monitoring. The market for CGM is highly competitive, with existing short-term needle-type CGMs and traditional glucometers. Profusa's Lumee Glucose platform aims to differentiate itself with a single-injection, long-term sensor, potentially offering a more convenient and cost-effective alternative. The Lumee Oxygen platform addresses critical limb ischemia (CLI) and peripheral artery disease (PAD), areas with significant unmet medical needs. The company's strategy to target both direct-to-hospital and direct-to-pharmacy sales for Lumee Glucose, along with seeking CPT codes, reflects an understanding of market access challenges in the medical device industry. The global economic environment, characterized by high inflation and tightening monetary policies, presents a challenging backdrop for companies seeking additional financing, which is a critical need for Profusa.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Profusa's financial performance or product development against industry standards.
• The Lumee Glucose platform's claim of continuous glucose monitoring with only an initial single injection for several months is presented as an attractive alternative to current short-term needle-type CGMs requiring weekly sensor replacement and frequent finger sticks, implying a competitive advantage in convenience and potentially cost.
• The company's strategy to pursue both direct-to-hospital and direct-to-pharmacy sales for Lumee Glucose, and to seek CPT codes for sensor insertion, indicates an awareness of market access and reimbursement strategies common in the medical device industry.

Related Party Transactions

• Convertible notes, Tasly convertible debt, and promissory notes were issued to certain shareholders.
• Tasly Holding Group (Tasly) is a related party, involved in the Tasly Convertible Debt and the expected APAC Joint Venture.
• As of June 30, 2025, $14.1 million of outstanding convertible notes and $10.0 million of senior notes were with related parties.
• The Tasly Convertible Debt is a short-term loan agreement with a related party, under which the company borrowed up to $1.6 million.

Stakeholder Impact

• Shareholders: Subject to lock-up agreements for 6 months post-merger, with potential for early release. Existing Profusa shareholders received New Profusa Common Stock at an exchange ratio of approximately 0.34. Potential for dilution from future equity raises (ELOC).
• Employees: Research and development personnel costs decreased due to a reduction in personnel, potentially impacting employee morale or future hiring. Stock-based compensation is a component of employee remuneration.
• Creditors: The company is in default on its PPP Loan 2 and Tasly Convertible Debt, indicating elevated credit risk. Convertible debt holders converted their debt into equity as part of the merger.
• Customers: Potential for new product offerings (Lumee Glucose) and expanded market access (Europe for Lumee Oxygen/Glucose).
• Suppliers: Accounts payable increased significantly, potentially impacting supplier relationships if payments are delayed.

Next Steps

• Continue substantial investments in building European and United States commercial infrastructure.
• Enhance existing products and develop new ones.
• Continue discussions with potential partners in Asia for the APAC Joint Venture, with a revised deadline of December 31, 2025.
• Seek additional equity or debt financing for future capital needs, especially for periods beyond twelve months from the financial statements' issuance.
• Apply for forgiveness for PPP Loan 2.
• Work towards achieving the revised earnout revenue target of $11,864,000 for Milestone Event IV for the fiscal year ended December 31, 2026.
• Utilize the Equity Line of Credit with Ascent to raise up to $100 million, with proceeds potentially used for Bitcoin purchases if cash balance exceeds $5 million.

Key Dates

Recommendation

The company has completed a significant business combination and secured a substantial potential capital raise facility (ELOC), which are positive steps for its long-term viability and product commercialization. However, the immediate financial results show increasing losses, a large working capital deficit, and management's explicit acknowledgment of ongoing going concern doubts. While the ELOC provides a pathway for future funding, the terms (97% of VWAP, Bitcoin purchase clause) suggest a potentially dilutive and speculative financing strategy. The company's core products (biosensing, CGM) are in attractive markets, but significant execution risk remains in clinical trials, regulatory approvals, and commercialization. Given the mixed signals – strategic progress offset by severe financial distress and high execution risk – a 'hold' recommendation is appropriate for investors who already have exposure, awaiting clearer signs of financial stabilization and successful product commercialization. New investors should exercise extreme caution.

Keywords

Biosensing, Medical Technology, Digital Health, Continuous Glucose Monitoring (CGM), Lumee Oxygen, Lumee Glucose, SEC Filing, 8-K/A, Merger, Business Combination, Lock-Up Agreement, Going Concern, Financial Results, Liquidity, Capital Raise, Equity Line of Credit (ELOC), Profusa, NorthView Acquisition Corp., FDA Approval, CE Mark, Clinical Trials, Risk Factors, Related Party Transactions